| Autor: |
N. Wainman, Gregory Cairncross, Peter A. Forsyth, David R. Macdonald, Douglas A. Stewart, C. Sawka, Eric L. Eisenhauer |
| Rok vydání: |
1996 |
| Předmět: |
|
| Zdroj: |
Annals of Oncology. 7:205-207 |
| ISSN: |
0923-7534 |
| Popis: |
Summary Background The NCIC Clinical Trials Group has an ongoing interest in assessing investigational agents in minimally pretreated patients with malignant glioma. Topotecan is one of the first topoisomerase I inhibitors to enter clinical trials and has shown early evidence of activity in several solid tumors. We have conducted a phase II trial of topotecan in patients with malignant glioma. Methods Adults with malignant glioma and recurrent contrast enhancing measurable disease (≥2 × 2 cm) were eligible. Topotecan 1.5 mg/m2 i.v. was given daily × five days every three weeks. Response and toxic effects were assessed at the end of each cycle. Results Thirty-one patients were entered onto the study: fifteen had glioblastoma, 16 anaplastic astrocytoma, all had prior radiation, 15 prior chemotherapy, and all were assessable for response and toxicity. Two patients (6%) responded: one had a complete radiographic response, but died with neutropenic sepsis, and the second had a prolonged partial response (>97 weeks). Twenty-one patients (68%) had stable disease for five to 86+ weeks (median 19) and eight (26%) had progressive disease after one cycle. Toxicity was primarily hematologic; 18 (58%) had grade 4 neutropenia ( |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
